Midazolam hydrochloride

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Atopic DermatitisBipolar DisorderDepressionAmnesia

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Phase 3

12

Eucrisa

AAnacor

Phase 3

43

Amlitelimab

Sanofi

Phase 3

64

Ciclosporin

Novartis

Phase 3

45

Calcineurin Inhibitors

Sanofi

Phase 3

16

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

47

Rocatinlimab

Amgen

Phase 3

88

Pegcrisantaspase

Jazz Pharmaceuticals

Phase 3

19

SHR-1819

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

410

EBGLYSS

Eli Lilly

Preclinical

23Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01218620·17 enrolled

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Recruiting·PPMV Pharmaceuticals, Inc·Phase 1·NCT07372625·14 enrolled

Caffeine1 trial

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers

Completed·Boehringer Ingelheim·Phase 1·NCT02256813·20 enrolled

Intravenous1 trial

Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery

Completed·—·Phase 1·NCT06867068·73 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Intranasal Dexmedetomidine

Unknown status·UUnknown Sponsor·Phase 4·NCT02985697·100 enrolled

Treatment1 trial

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

Unknown status·MMedical University of Vienna·Phase 2·NCT02992496·60 enrolled

11 more indications

Amnesia1 trial

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00142493·79 enrolled

Atopic Dermatitis1 trial

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Completed·LEO Pharma·Phase 1·NCT03556592·40 enrolled

Suicidality1 trial

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT04592809·50 enrolled

Methamphetamine Use Disorder1 trial

Ketamine for Methamphetamine Use Disorder

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06496750·120 enrolled

Midazolam1 trial

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Completed·Roche·Phase 1·NCT03330990·15 enrolled

Laparoscopic Cholecystectomy1 trial

Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia

Unknown status·FFederal University of São Paulo·Phase 4·NCT02953210·40 enrolled

Treatment Resistant Depression1 trial

i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06480500·110 enrolled

Bipolar Disorder1 trial

Ketamine for Treatment-Resistant Bipolar Disorder

Completed·JJoshua Rosenblat·Phase 2·NCT05004896·71 enrolled

Single Dose1 trial

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

Completed·Daiichi Sankyo·Phase 1·NCT02473627·18 enrolled

Depression1 trial

Ketamine for Combined Depression and Alcohol Use Disorder: A Blinded Randomized Active Placebo-controlled Trial (the KeDA Trial)

Recruiting·UUniversity Hospital of North Norway·Preclinical·NCT06090422·34 enrolled

Unspecified1 trial

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Completed·CCorcept Therapeutics·Phase 1·NCT03457597·27 enrolled

Details

Drug Info

Related News